| Wissenschaftl. Titel | A phase 1b trial of Mavorixafor, an oral CXCR4 antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations in MYD88 and CXCR4 A study of Mavorixafor in combination with Ibrutinib in participants with Waldenstrom's Macroglobulinemia (WM) whose Tumors Express Mutations in MYD88 and CXCR4 |
| Erkrankung |
Haema:
NHL: diffuses, großzelliges B-Zell-Lymphom:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (U) Weiterführende Informationen (NIH) |
erstellt 25.10.2022 Data entry III CCP
geändert 05.07.2023 Data entry IX CCP